Compare Adaptive Biotechnologies Corp (ADPT) vs Allegion PLC (ALLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Allegion PLC — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Allegion PLC trades at $135.08 (market cap $11.97B). The key difference: Allegion PLC is far larger — about 3.6× Adaptive Biotechnologies Corp's market cap, and Allegion PLC pays a 1.52% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ALLE | |
|---|---|---|
Market Cap | $3.33B | $11.97B |
Sector | Health | Industrials |
52-Week High | $22.37 | $179.77 |
52-Week Low | $10.24 | $125.65 |
Enterprise Value | $3.19B | $13.69B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ALLE trades at $139.32, down 0.9% on the day, with a bullish technical signal and strong fundamentals including a 15.24% net margin and 34.18% ROE. Recent earnings show mixed results with a Q3 2025 beat but Q4 2025 and Q1 2026 misses. The company maintains robust cash flow from operations and has announced a $0.55 dividend for June 2026. News highlights product innovations like the Schlage Sense Pro smart deadbolt and participation in industry conferences.
Outlook is supported by analyst consensus with a $152.50 price target and no sell ratings, though risks include rising costs and international market weakness. The stock offers growth potential from Americas strength and acquisitions, but investors should monitor margin pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
